Alison C Kearns1, Fengming Liu1,2, Shen Dai1, Jake A Robinson1, Elizabeth Kiernan1, Lediya Tesfaye Cheru3, Xiao Peng1, Jennifer Gordon1, Susan Morgello4,5,6, Aishazhan Abuova4,5,6, Janet Lo3, Markella V Zanni3, Steven K Grinspoon3, Tricia H Burdo1, Xuebin Qin 秦学斌1,2. 1. From the Department of Neuroscience, Lewis Katz School of Medicine at Temple University, Philadelphia, PA (A.C.K., F.L., S.D., J.A.R., E.K., X.P., J.G., T.H.B., X.Q.). 2. Division of Pathology, Tulane National Primate Research Center, Covington, LA (F.L., X.Q.). 3. Program in Nutritional Metabolism, Division of Endocrinology, Mass General Hospital, Harvard Medical School, Boston, MA (L.T.C., J.L., M.V.Z., S.K.G.). 4. Departments of Neurology (S.M., A.A.), Mount Sinai Medical Center, New York, NY. 5. Neuroscience (S.M., A.A.), Mount Sinai Medical Center, New York, NY. 6. Pathology (S.M., A.A.), Mount Sinai Medical Center, New York, NY.
Abstract
OBJECTIVE: Atherosclerotic cardiovascular disease (ASCVD) is an increasing cause of morbidity and mortality in people with HIV since the introduction of combination antiretroviral therapy. Despite recent advances in our understanding of HIV ASCVD, controversy still exists on whether this increased risk of ASCVD is due to chronic HIV infection or other risk factors. Mounting biomarker studies indicate a role of monocyte/macrophage activation in HIV ASCVD; however, little is known about the mechanisms through which HIV infection mediates monocyte/macrophage activation in such a way as to engender accelerated atherogenesis. Here, we experimentally investigated whether HIV expression is sufficient to accelerate atherosclerosis and evaluated the role of caspase-1 activation in monocytes/macrophages in HIV ASCVD. Approach and Results: We crossed a well-characterized HIV mouse model, Tg26 mice, which transgenically expresses HIV-1, with ApoE-/- mice to promote atherogenic conditions (Tg26+/-/ApoE-/-). Tg26+/-/ApoE-/- have accelerated atherosclerosis with increased caspase-1 pathway activation in inflammatory monocytes and atherosclerotic vasculature compared with ApoE-/-. Using a well-characterized cohort of people with HIV and tissue-banked aortic plaques, we documented that serum IL (interleukin)-18 was higher in people with HIV compared with non-HIV-infected controls, and in patients with plaques, IL-18 levels correlated with monocyte/macrophage activation markers and noncalcified inflammatory plaques. In autopsy-derived aortic plaques, caspase-1+ cells and CD (clusters of differentiation) 163+ macrophages correlated. CONCLUSIONS: These data demonstrate that expression of HIV is sufficient to accelerate atherogenesis. Further, it highlights the importance of caspase-1 and monocyte/macrophage activation in HIV atherogenesis and the potential of Tg26+/-/ApoE-/- as a tool for mechanistic studies of HIV ASCVD.
OBJECTIVE: Atherosclerotic cardiovascular disease (ASCVD) is an increasing cause of morbidity and mortality in people with HIV since the introduction of combination antiretroviral therapy. Despite recent advances in our understanding of HIV ASCVD, controversy still exists on whether this increased risk of ASCVD is due to chronic HIV infection or other risk factors. Mounting biomarker studies indicate a role of monocyte/macrophage activation in HIV ASCVD; however, little is known about the mechanisms through which HIV infection mediates monocyte/macrophage activation in such a way as to engender accelerated atherogenesis. Here, we experimentally investigated whether HIV expression is sufficient to accelerate atherosclerosis and evaluated the role of caspase-1 activation in monocytes/macrophages in HIV ASCVD. Approach and Results: We crossed a well-characterized HIV mouse model, Tg26 mice, which transgenically expresses HIV-1, with ApoE-/- mice to promote atherogenic conditions (Tg26+/-/ApoE-/-). Tg26+/-/ApoE-/- have accelerated atherosclerosis with increased caspase-1 pathway activation in inflammatory monocytes and atherosclerotic vasculature compared with ApoE-/-. Using a well-characterized cohort of people with HIV and tissue-banked aortic plaques, we documented that serum IL (interleukin)-18 was higher in people with HIV compared with non-HIV-infected controls, and in patients with plaques, IL-18 levels correlated with monocyte/macrophage activation markers and noncalcified inflammatory plaques. In autopsy-derived aortic plaques, caspase-1+ cells and CD (clusters of differentiation) 163+ macrophages correlated. CONCLUSIONS: These data demonstrate that expression of HIV is sufficient to accelerate atherogenesis. Further, it highlights the importance of caspase-1 and monocyte/macrophage activation in HIV atherogenesis and the potential of Tg26+/-/ApoE-/- as a tool for mechanistic studies of HIV ASCVD.
Entities:
Keywords:
HIV infections; atherosclerosis; humans; macrophages; mice; monocytes
Authors: Claudio Napoli; Filomena de Nigris; John S Welch; Federico B Calara; Robert O Stuart; Christopher K Glass; Wulf Palinski Journal: Circulation Date: 2002-03-19 Impact factor: 29.690
Authors: Janet Lo; Suhny Abbara; Leon Shturman; Anand Soni; Jeffrey Wei; Jose A Rocha-Filho; Khurram Nasir; Steven K Grinspoon Journal: AIDS Date: 2010-01-16 Impact factor: 4.177
Authors: Tricia H Burdo; Margaret R Lentz; Patrick Autissier; Anitha Krishnan; Elkan Halpern; Scott Letendre; Eric S Rosenberg; Ronald J Ellis; Kenneth C Williams Journal: J Infect Dis Date: 2011-07-01 Impact factor: 5.226
Authors: Florencia Pereyra; Janet Lo; Virginia A Triant; Jeffrey Wei; Maria J Buzon; Kathleen V Fitch; Janice Hwang; Jennifer H Campbell; Tricia H Burdo; Kenneth C Williams; Suhny Abbara; Steven K Grinspoon Journal: AIDS Date: 2012-11-28 Impact factor: 4.177
Authors: J B Kopp; M E Klotman; S H Adler; L A Bruggeman; P Dickie; N J Marinos; M Eckhaus; J L Bryant; A L Notkins; P E Klotman Journal: Proc Natl Acad Sci U S A Date: 1992-03-01 Impact factor: 11.205
Authors: Priscilla Y Hsue; Peter W Hunt; Amanda Schnell; S Craig Kalapus; Rebecca Hoh; Peter Ganz; Jeffrey N Martin; Steven G Deeks Journal: AIDS Date: 2009-06-01 Impact factor: 4.177
Authors: Gongxiong Wu; Weiguo Hu; Aliakbar Shahsafaei; Wenping Song; Martin Dobarro; Galina K Sukhova; Rod R Bronson; Guo-Ping Shi; Russell P Rother; Jose A Halperin; Xuebin Qin Journal: Circ Res Date: 2009-01-08 Impact factor: 17.367
Authors: Shen Dai; Fengming Liu; Mi Ren; Zhongnan Qin; Namita Rout; Xiao-Feng Yang; Hong Wang; Stephen Tomlinson; Xuebin Qin Journal: Front Cardiovasc Med Date: 2021-09-28